{ "id": "SQ-LIP-000036", "question": "Is lipedema onset influenced by heredity and family history?", "question_pt": "O início do lipedema é influenciado por hereditariedade e história familiar?", "phrasings": [], "phrasings_pt": [], "knowledge_state": "emerging", "tags": [ "Etiology", "Genetics", "Hormones" ], "keywords": [ "heredity", "family history", "inheritance", "lipedema onset" ], "current_answer": "Based on currently indexed evidence, lipedema onset appears to be influenced by heredity and family history, though the evidence is predominantly descriptive and the precise genetic architecture remains undefined. Multiple sources consistently report frequent positive family history among affected women, with reported familial prevalence ranging widely across studies (≈15% of first-degree relatives in one systematic review; 14.9% with an affected first-degree relative in a 67-proband series; 46% in a Saudi cross-sectional study; and up to 60–64% suggesting autosomal dominant inheritance in some reviews; broader review estimates span 30–89%). Affected relatives are almost exclusively female, and several pedigree/linkage analyses favor autosomal dominant inheritance with incomplete penetrance and sex limitation, while X-linked dominant inheritance was excluded in one family. The strongest-quality evidence comes from genome-wide association studies: a GWAS of an inferred lipedema phenotype in UK Biobank (moderate grade) reported SNP heritability of ~5.13% and 18 genome-wide significant loci (e.g., RSPO3, GRB14-COBLL1, VEGFA, ADAMTS9), and a dedicated GWAS in a clinically-defined UK cohort (moderate grade) identified a suggestive, replicated locus near LHFPL6. Family-based exome sequencing supports polygenic genetic heterogeneity rather than a single Mendelian cause, with rare familial variants (notably AKR1C1 p.L213Q segregating in one family) reported in individual pedigrees. Collectively the evidence supports a hereditary/familial contribution to lipedema onset, frequently intertwined with hormonal transition periods, but no confirmed causal gene for primary non-syndromic lipedema has been established.", "current_answer_pt": "Com base nas evidências atualmente indexadas, o início do lipedema parece ser influenciado por hereditariedade e história familiar, embora as evidências sejam predominantemente descritivas e a arquitetura genética precisa permaneça indefinida. Múltiplas fontes relatam consistentemente história familiar positiva frequente entre mulheres afetadas, com prevalência familiar variando amplamente entre estudos (≈15% de parentes de primeiro grau em uma revisão sistemática; 14,9% com parente de primeiro grau afetado em uma série de 67 probandos; 46% em estudo transversal saudita; e até 60–64% sugerindo herança autossômica dominante em algumas revisões; estimativas de revisões mais amplas vão de 30–89%). Parentes afetados são quase exclusivamente do sexo feminino, e várias análises de pedigree/ligação favorecem herança autossômica dominante com penetrância incompleta e limitação ao sexo, enquanto a herança dominante ligada ao X foi excluída em uma família. As evidências de maior qualidade vêm de estudos de associação genômica ampla (GWAS): um GWAS de fenótipo de lipedema inferido no UK Biobank (qualidade moderada) relatou herdabilidade SNP de ~5,13% e 18 loci significativos (ex.: RSPO3, GRB14-COBLL1, VEGFA, ADAMTS9), e um GWAS dedicado em coorte britânica clinicamente definida (qualidade moderada) identificou um locus sugestivo e replicado próximo ao LHFPL6. O sequenciamento de exoma baseado em famílias apoia heterogeneidade genética poligênica em vez de uma causa mendeliana única, com variantes familiares raras (notavelmente AKR1C1 p.L213Q segregando em uma família) relatadas em pedigrees individuais. Em conjunto, as evidências apoiam uma contribuição hereditária/familiar ao início do lipedema, frequentemente entrelaçada com períodos de transição hormonal, mas nenhum gene causal confirmado para o lipedema primário não-sindrômico foi estabelecido.", "bottom_line": "Multiple studies consistently show that lipedema runs in families and that genetic factors contribute to its onset, with genome-wide studies identifying several candidate regions and supporting a hereditary component, most likely through an autosomal dominant pattern with incomplete expression in males. The exact genes responsible have not been confirmed, family-history estimates vary wildly across studies (15–89%) due to methodological differences, and it is unclear whether the genetic signals found are specific to lipedema or shared with general fat distribution traits.", "bottom_line_pt": "Vários estudos mostram de forma consistente que a lipedema tem tendência familiar e que fatores genéticos contribuem para o seu aparecimento, com estudos genômicos identificando regiões candidatas e sugerindo um padrão de herança autossômico dominante com expressão incompleta em homens. Os genes exatos responsáveis ainda não foram confirmados, as estimativas de histórico familiar variam muito entre estudos (15–89%) por diferenças metodológicas, e não está claro se os sinais genéticos encontrados são específicos da lipedema ou compartilhados com traços gerais de distribuição de gordura.", "major_uncertainty": "The mode of inheritance and causal genes are unresolved: family-history prevalence estimates vary enormously (15–89%) across mostly descriptive, unadjusted cross-sectional surveys, case series, and narrative reviews with high risk of selection/recall bias. GWAS loci explain only a small fraction of heritability (~5%), several signals are only suggestive and unreplicated, and rare familial variants (e.g., AKR1C1) come from single families/case reports. No confirmed gene for primary non-syndromic lipedema exists, and whether identified loci are causal or shared with general adiposity remains unclear.", "version": "1.1", "created": "2026-06-02", "updated": "2026-06-02", "compiled_by": { "model": "anthropic/claude-opus-4.8", "label": "Claude Opus 4.8", "date": "2026-06-02" }, "outcomes": [], "evidence_direction": { "supporting": 21, "contradicting": 0, "other": 0 }, "knowledge_freshness": { "pct": 71, "sources": 24, "newest": 2026, "oldest": 2010, "small_base": false, "label": "current evidence base" }, "claims": [ { "id": "SCR-LIP-000004", "role": "supporting", "statement": "Lipedema is a multifactorial disorder whose symptoms are closely linked to female hormonal transitions (puberty, pregnancy, menopause) and to chronic low-grade inflammation, on a polygenic predisposition." }, { "id": "SCR-LIP-000046", "role": "supporting", "statement": "Several findings suggest a hereditary predisposition to lipedema, with frequent family history among affected women." }, { "id": "SCR-LIP-000109", "role": "supporting", "statement": "A systematic review identified four distinct pathophysiological hypotheses linking hormonal dysregulation—particularly estrogen metabolism and receptor function, growth hormone imbalance, and adipokine/leptin-related adipose stem cell alterations—to lipedema development, with possible genetic susceptibility components." }, { "id": "SCR-LIP-000110", "role": "supporting", "statement": "Lipedema is described as an estrogen-regulated polygenic disorder that manifests almost exclusively in women, with onset at hormonal transition phases (puberty, pregnancy, menopause), family aggregation in at least 16% of cases, and a pathological ERα/ERβ receptor pattern in white adipose tissue driving site-specific lipogenesis." }, { "id": "SCR-LIP-000153", "role": "supporting", "statement": "In a survey of 209 lipedema patients, symptom onset clustered in adolescence (mean age 16±9 years, 32.5% at ages 14-18), family history was common (affected grandmothers 35.4%, mothers 29.7%, aunts 23.0%), and 30.5% of premenopausal patients had sex-hormone imbalances, consistent with hormonal and hereditary contributions to lipedema onset." }, { "id": "SCR-LIP-000154", "role": "supporting", "statement": "This critical review proposes an integrative pathomechanism in which lipedema is an estrogen-regulated polygenetic disease, citing up to 60% of cases suggesting autosomal dominant inheritance with incomplete penetrance (Child et al., 330 relatives) and manifestation paralleling feminine hormonal changes, alongside estrogen receptor differences (decreased ERα, increased ERβ in the gluteal region) and animal models (PROX1+/-, VEGFR-3 mutants)." }, { "id": "SCR-LIP-000141", "role": "supporting", "statement": "In a Saudi cross-sectional study of 115 patients with lower-limb edema, lipedema was clinically confirmed in 71%, affected only women with mean age 38.6 years and mean BMI 30.5, with disease onset typically at ages 20-39, perceived triggers being puberty (49%), pregnancy (22%), and massive weight loss (22%), a positive family history in 46% (predominantly mothers and sisters), and 77% being previously undiagnosed." }, { "id": "SCR-LIP-000157", "role": "supporting", "statement": "This systematic review reports familial incidence of lipedema in 15% of first-degree female relatives consistent with X-linked dominant or autosomal dominant inheritance with incomplete penetrance, identifies an AKR1C1 missense variant (a gene involved in progesterone metabolism) as the first mutated gene in a family with primary non-syndromic lipedema, and notes hormonal/progesterone-pathway involvement." }, { "id": "SCR-LIP-000219", "role": "supporting", "statement": "In a series of 67 probands, 14.9% had at least one affected first-degree relative (all affected relatives female), X-chromosome linkage analysis in the largest family excluded X-linked dominant inheritance (lod scores < -2) favoring autosomal dominant inheritance with sex limitation, and onset at puberty in 55% of probands plus near-exclusive female occurrence suggested estrogen-dependent expression." }, { "id": "SCR-LIP-000220", "role": "supporting", "statement": "This narrative review reports genetic evidence (305 candidate genes via next-generation sequencing in 162 patients; 18 GWAS risk loci including VEGFA and GRB14-COBLL1 validated in UK Biobank; monogenic AKR1C1 and PIT1 mutations affecting progesterone and growth-hormone/prolactin pathways) supporting both hereditary and hormonal influences on lipedema onset." }, { "id": "SCR-LIP-000222", "role": "supporting", "statement": "This comparative narrative review reports that lipedema is almost exclusively found in women and typically begins during periods of hormonal change (puberty, pregnancy, menopause), and notes heritability/genetic markers as part of its genetics domain." }, { "id": "SCR-LIP-000223", "role": "supporting", "statement": "This multidisciplinary review reports that lipedema shows familial history in 30-89% of cases with polygenic GWAS findings (loci in CPE, ZNF25, ZNF33A linked to estrogen biology, plus VEGFA and GRB14-COBLL1, and an AKR1C1 missense variant) and that onset or worsening clusters at hormonal transitions—puberty (15.7-67.3%), pregnancy/lactation (9.5-63.1%), and menopause (1.9-21%)—with estradiol altering ERα/ERβ and PPAR-γ2 expression in lipedema-derived adipose stem cells." }, { "id": "SCR-LIP-000224", "role": "supporting", "statement": "In a rigorously defined UK lipedema cohort (n=130), onset was frequently associated with hormonal changes (puberty, pregnancy, menopause), and the first dedicated GWAS identified a suggestive genetic locus (rs1409440, OR_meta 2.01, P_meta 4×10⁻⁶) upstream of LHFPL6, replicated in an independent 100,000 Genomes cohort." }, { "id": "SCR-LIP-000225", "role": "supporting", "statement": "This review proposes that dysregulated estrogen signaling in adipose tissue—via an increased ERα/ERβ ratio in gluteofemoral adipocytes or excessive local paracrine estrogen production by adipocyte steroidogenic enzymes—drives the excessive subcutaneous fat accumulation in lipedema, and cites whole-exome sequencing linking lipedema to variants in sex hormone genes, with onset coinciding with hormonal fluctuation periods such as puberty, pregnancy, and menopause." }, { "id": "SCR-LIP-000226", "role": "supporting", "statement": "A GWAS of an inferred lipedema phenotype in UK Biobank women identified 18 genome-wide significant loci (SNP heritability ~5.13%), including RSPO3 (OR=1.24), GRB14-COBLL1, VEGFA, and ADAMTS9 (some replicated in an independent clinically-diagnosed lipedema cohort), with genetic correlations to body fat, leptin levels, and age at menopause." }, { "id": "SCR-LIP-000215", "role": "supporting", "statement": "Family-based exome sequencing of 31 individuals from 9 lipedema families identified candidate variants in 469 genes with no single gene shared across all families, supporting genetic heterogeneity rather than a Mendelian single-gene cause, with gene ontology enrichment in vasopressin receptor activity (AVPR1A, AVPR2), microfibril binding (FBN, ELN, LTBP), and patched binding (PTCH1/2, Hedgehog pathway)." }, { "id": "SCR-LIP-000238", "role": "supporting", "statement": "This systematic review reports that lipedema most likely follows autosomal dominant inheritance with incomplete penetrance and sex limitation (positive family history in up to 64% of women), identifies no confirmed gene for primary non-syndromic lipedema, and catalogs syndromic associations (POU1F1A c.196C>T p.Pro24Leu; NSD1 p.Cys2175Ser/Sotos; 7q11.23 deletion/Williams-Beuren with ELN, FZD9, MLXIPL; ABCC6/PXE; ALDH18A1/cutis laxa III) plus 17 GWAS/animal-model candidate genes (e.g., LYPLAL1, TBX15, HOXC13, RSPO3, VEGFA, PROX1, VEGFR3, PRDM16)." }, { "id": "SCR-LIP-000229", "role": "supporting", "statement": "This narrative review reports that lipedema onset is associated with periods of hormonal fluctuation (puberty, pregnancy, menopause) and describes estrogen-dependent mechanisms (increased aromatase CYP19A1, estrogen-induced ZNF423 hyperproliferation), alongside a proposed female-preferential autosomal dominant inheritance pattern." }, { "id": "SCR-LIP-000231", "role": "supporting", "statement": "This review proposes AKR1C enzymes (AKR1C1-4) as a central biological pathway linking rare familial mutations (e.g., AKR1C1 L213Q segregating with lipedema across 3 generations, AKR1C2 Ser320PheTer2) and common regulatory polymorphisms (rs28571848, rs34477787) to lipedema through altered steroid hormone metabolism in gluteofemoral subcutaneous adipose tissue, with environmental endocrine disruptors and hormones converging on the same hereditary pathway." }, { "id": "SCR-LIP-000314", "role": "supporting", "statement": "This narrative review proposes that lipedema involves a common genetic alteration—an imbalance of estradiol receptors (ERα > ERβ) in adipose tissue present in all cases—combined with physiological hormonal fluctuations (puberty, pregnancy, menopause), endocrine disruptors, and estrogen-dependent gynecological disorders, citing associations such as menstrual irregularities (43%) and PCOS (17%) in women with lipedema." }, { "id": "SCR-LIP-000315", "role": "supporting", "statement": "Whole-exome sequencing in a family with autosomal dominant nonsyndromic primary lipedema identified the AKR1C1 c.638T>A (p.L213Q) variant segregating perfectly with the disease in 3 affected members (puberty onset in all) and absent in 9 unaffected members, with molecular dynamics and QSAR predicting partial loss of 20α-HSD function that may promote lipogenesis via reduced progesterone catabolism." } ], "references": [ "DOI:10.1590/1677-5449.202301832", "DOI:10.53347/rid-217362", "DOI:10.1007/s00404-026-08318-1", "DOI:10.1055/a-0767-6842", "DOI:10.1097/prs.0000000000006280", "DOI:10.1016/j.mehy.2014.08.011", "DOI:10.1097/gox.0000000000006173", "DOI:10.3390/jpm13010098", "DOI:10.1002/ajmg.a.33313", "DOI:10.1111/obr.13953", "DOI:10.3390/ijms23126621", "DOI:10.1038/s44324-025-00093-y", "DOI:10.1371/journal.pone.0274867", "DOI:10.1101/2021.06.15.21258988", "DOI:10.3390/ijms222111720", "DOI:10.1038/s41431-022-01231-6", "DOI:10.1089/lrb.2023.0065", "DOI:10.26355/eurrev_201907_18292", "DOI:10.3390/biomedicines10123081", "DOI:10.4081/vl.2026.15495", "DOI:10.9734/jammr/2025/v37i25731", "DOI:10.3390/ijms21176264" ], "cite": "Scientific Claim Registry. Is lipedema onset influenced by heredity and family history?. SQ-LIP-000036 v1.1; 2026-06-02. https://scientificclaims.org/q/SQ-LIP-000036/v1.1.html", "versions": [ { "version": "1.1", "date": "2026-06-02", "url": "https://scientificclaims.org/q/SQ-LIP-000036/v1.1.html" }, { "version": "1.0", "date": "2026-06-02", "url": "https://scientificclaims.org/q/SQ-LIP-000036/v1.0.html" } ], "url": "https://scientificclaims.org/q/SQ-LIP-000036.html", "url_pt": "https://scientificclaims.org/pt/q/SQ-LIP-000036.html", "version_url": "https://scientificclaims.org/q/SQ-LIP-000036/v1.1.html", "license": "CC-BY-4.0", "disclaimer": "Evidence-bounded summary; not medical advice." }